AMPHASTAR PHARMACEUTICALS IN (AMPH) Fundamental Analysis & Valuation
NASDAQ:AMPH • US03209R1032
Current stock price
20.45 USD
+0.21 (+1.04%)
At close:
20.45 USD
0 (0%)
After Hours:
This AMPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AMPH Profitability Analysis
1.1 Basic Checks
- In the past year AMPH was profitable.
- In the past year AMPH had a positive cash flow from operations.
- In the past 5 years AMPH has always been profitable.
- Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
- AMPH's Return On Assets of 6.02% is amongst the best of the industry. AMPH outperforms 86.98% of its industry peers.
- Looking at the Return On Equity, with a value of 12.44%, AMPH belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 7.81%, AMPH belongs to the top of the industry, outperforming 86.46% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for AMPH is below the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.02% | ||
| ROE | 12.44% | ||
| ROIC | 7.81% |
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
1.3 Margins
- AMPH has a Profit Margin of 13.63%. This is amongst the best in the industry. AMPH outperforms 86.98% of its industry peers.
- AMPH's Profit Margin has improved in the last couple of years.
- AMPH has a better Operating Margin (19.50%) than 86.98% of its industry peers.
- AMPH's Operating Margin has improved in the last couple of years.
- AMPH has a better Gross Margin (49.46%) than 64.58% of its industry peers.
- AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.5% | ||
| PM (TTM) | 13.63% | ||
| GM | 49.46% |
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
2. AMPH Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
- Compared to 1 year ago, AMPH has less shares outstanding
- The number of shares outstanding for AMPH has been reduced compared to 5 years ago.
- AMPH has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.31 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
- AMPH has a Altman-Z score of 2.31. This is in the better half of the industry: AMPH outperforms 64.58% of its industry peers.
- AMPH has a debt to FCF ratio of 5.13. This is a neutral value as AMPH would need 5.13 years to pay back of all of its debts.
- The Debt to FCF ratio of AMPH (5.13) is better than 82.81% of its industry peers.
- A Debt/Equity ratio of 0.77 indicates that AMPH is somewhat dependend on debt financing.
- The Debt to Equity ratio of AMPH (0.77) is worse than 69.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.13 | ||
| Altman-Z | 2.31 |
ROIC/WACC0.92
WACC8.53%
2.3 Liquidity
- AMPH has a Current Ratio of 4.02. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
- AMPH has a Current ratio of 4.02. This is comparable to the rest of the industry: AMPH outperforms 59.38% of its industry peers.
- AMPH has a Quick Ratio of 2.90. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
- AMPH has a Quick ratio (2.90) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 2.9 |
3. AMPH Growth Analysis
3.1 Past
- The earnings per share for AMPH have decreased strongly by -15.80% in the last year.
- AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 38.40% yearly.
- AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -1.65%.
- The Revenue has been growing by 15.53% on average over the past years. This is quite good.
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.20% on average over the next years.
- AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.48% yearly.
EPS Next Y3.95%
EPS Next 2Y5%
EPS Next 3Y6.42%
EPS Next 5Y-1.2%
Revenue Next Year4.06%
Revenue Next 2Y4.41%
Revenue Next 3Y4.13%
Revenue Next 5Y4.48%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. AMPH Valuation Analysis
4.1 Price/Earnings Ratio
- AMPH is valuated cheaply with a Price/Earnings ratio of 6.29.
- Based on the Price/Earnings ratio, AMPH is valued cheaper than 94.79% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 25.60. AMPH is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 6.05, the valuation of AMPH can be described as very cheap.
- AMPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.23% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.84. AMPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.29 | ||
| Fwd PE | 6.05 |
4.2 Price Multiples
- AMPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPH is cheaper than 95.83% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 95.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.8 | ||
| EV/EBITDA | 5.8 |
4.3 Compensation for Growth
- AMPH's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.59
PEG (5Y)0.16
EPS Next 2Y5%
EPS Next 3Y6.42%
5. AMPH Dividend Analysis
5.1 Amount
- AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AMPH Fundamentals: All Metrics, Ratios and Statistics
20.45
+0.21 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)05-05 2026-05-05
Inst Owners76.52%
Inst Owner Change-0.32%
Ins Owners9.5%
Ins Owner Change4.01%
Market Cap927.82M
Revenue(TTM)719.89M
Net Income(TTM)98.09M
Analysts76.92
Price Target29.58 (44.65%)
Short Float %11.01%
Short Ratio7.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.91%
Min EPS beat(2)-22.4%
Max EPS beat(2)10.58%
EPS beat(4)3
Avg EPS beat(4)1.57%
Min EPS beat(4)-22.4%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)2.84%
EPS beat(12)8
Avg EPS beat(12)9.98%
EPS beat(16)11
Avg EPS beat(16)14.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.97%
Min Revenue beat(2)-5.76%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)-0.48%
Revenue beat(16)8
Avg Revenue beat(16)-0.12%
PT rev (1m)-8.14%
PT rev (3m)-8.56%
EPS NQ rev (1m)-9.17%
EPS NQ rev (3m)-8.96%
EPS NY rev (1m)-9.06%
EPS NY rev (3m)-9.42%
Revenue NQ rev (1m)0.47%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)-0.75%
Revenue NY rev (3m)-1.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.29 | ||
| Fwd PE | 6.05 | ||
| P/S | 1.29 | ||
| P/FCF | 7.8 | ||
| P/OCF | 5.94 | ||
| P/B | 1.18 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | 5.8 |
EPS(TTM)3.25
EY15.89%
EPS(NY)3.38
Fwd EY16.52%
FCF(TTM)2.62
FCFY12.82%
OCF(TTM)3.44
OCFY16.83%
SpS15.87
BVpS17.39
TBVpS4.91
PEG (NY)1.59
PEG (5Y)0.16
Graham Number35.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.02% | ||
| ROE | 12.44% | ||
| ROCE | 9.54% | ||
| ROIC | 7.81% | ||
| ROICexc | 9.67% | ||
| ROICexgc | 18.47% | ||
| OM | 19.5% | ||
| PM (TTM) | 13.63% | ||
| GM | 49.46% | ||
| FCFM | 16.53% |
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
ROICexc(3y)13.25%
ROICexc(5y)14.34%
ROICexgc(3y)28.69%
ROICexgc(5y)24.19%
ROCE(3y)13.23%
ROCE(5y)13.72%
ROICexgc growth 3Y-3.07%
ROICexgc growth 5Y50.2%
ROICexc growth 3Y-19.69%
ROICexc growth 5Y34.74%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
F-Score6
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.13 | ||
| Debt/EBITDA | 3.09 | ||
| Cap/Depr | 65.49% | ||
| Cap/Sales | 5.16% | ||
| Interest Coverage | 6.05 | ||
| Cash Conversion | 79.21% | ||
| Profit Quality | 121.3% | ||
| Current Ratio | 4.02 | ||
| Quick Ratio | 2.9 | ||
| Altman-Z | 2.31 |
F-Score6
WACC8.53%
ROIC/WACC0.92
Cap/Depr(3y)81.11%
Cap/Depr(5y)91.09%
Cap/Sales(3y)5.56%
Cap/Sales(5y)5.56%
Profit Quality(3y)111.67%
Profit Quality(5y)103.97%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
EPS Next Y3.95%
EPS Next 2Y5%
EPS Next 3Y6.42%
EPS Next 5Y-1.2%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%
Revenue Next Year4.06%
Revenue Next 2Y4.41%
Revenue Next 3Y4.13%
Revenue Next 5Y4.48%
EBIT growth 1Y-31.65%
EBIT growth 3Y9.31%
EBIT growth 5Y66.42%
EBIT Next Year8.65%
EBIT Next 3Y3.07%
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3Y22.23%
FCF growth 5Y38.43%
OCF growth 1Y-26.84%
OCF growth 3Y20.52%
OCF growth 5Y22.21%
AMPHASTAR PHARMACEUTICALS IN / AMPH Fundamental Analysis FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
What is the valuation status for AMPH stock?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
What is the profitability of AMPH stock?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.
Can you provide the financial health for AMPH stock?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7 / 10.